Company
ASX:ATX
Amplia Therapeutics Limited is an Australian, clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases. The first of these drugs, narmafotinib (AMP945), is a highly selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF).
39 stories · page 2 of 2
Wood Mackenzie vice president Massimo Do Odoardo says that while the market will stay resilient in the short term, high prices will pressure demand and the rationale for China to switch from coal to gas will diminish.
The batch was produced on time and within budget and represents a big step up from the 1-kilogram batch that’s been manufactured under GMP conditions previously.
“Our priorities for 2022 are clear – our goal will be to build on the solid foundations of the last 12 months and maintain this momentum as we move towards two phase-two trials in the new year,” says CEO.
The low-interest Victorian Government loan scheme is designed to support small and medium enterprises investing in technologies deemed vital to the state's future growth.
Amplia has designed a Phase 2 clinical trial of AMP945 in pancreatic cancer patients and plans to initiate patient recruitment at Australian sites in the first quarter of calendar 2022.
The company is optimistic about the results of its Phase 1 clinical trial with results supporting further development of AMP945 as a treatment for cancer and fibrosis.
The data will be used to further refine the doses of AMP945 to be used in a Phase 2 clinical trial in patients with pancreatic cancer and will provide guidance for the Phase 2 trial in pulmonary fibrosis planned for the second half of 2022.
Proceeds from the placement and entitlement offer will be used to fund the first stage of a Phase 2 clinical trial for AMP945, manufacturing and further pre-clinical studies.
The company has also entered a trading halt as it undertakes a capital-raising process. The halt is in place until Monday, November 8, or when an announcement is released to the market.
José Iglesias MD will join the ATX team as a clinical advisor, providing more than 30 years of experience in the pharmaceutical industry.
The trial was completed during the first half of 2021 and leads into the company’s planned Phase 2 clinical trial in pancreatic cancer patients.
George will replace Jeff Carter, who is stepping down from the role after being the company’s CFO for more than eight years.
Cancer is estimated to cost nearly US$1 trillion worldwide every year, but a small group of ASX biotech stocks is working to change that.
FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus on pancreatic and ovarian cancer.
Both Amplia and Patrys have flagship drugs in development that take unique approaches to tackling cancers.
Join three emerging lifescience companies as they present their investment cases at Proactive's Lifesciences Webinar at 12pm AEST on Tuesday, September 28, 2021.
It is developing two proprietary, orally available, small molecule Focal Adhesion Kinase inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases.
The pharmaceutical company plans to initiate patient recruitment at Australian sites in the first quarter of 2022.
Amplia Therapeutics is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.
